Haleon plc Key Executives
This section highlights Haleon plc's key executives, including their titles and compensation details.
Find Contacts at Haleon plc
(Showing 0 of )
Haleon plc Earnings
This section highlights Haleon plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $25.25 | $0.05 |
| Read Transcript | Q2 | 2024 | 2024-08-02 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-02 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-29 | $10.27 | $6.54 |
| Read Transcript | Q2 | 2023 | 2023-08-02 | $0.22 | $0.08 |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
$10.28
Stock Price
$46.54B
Market Cap
10.35K
Employees
Weybridge, None
Location
Financial Statements
Access annual & quarterly financial statements for Haleon plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $11.23B | $11.30B | $10.86B | $9.54B | $9.89B |
| Cost of Revenue | $4.29B | $4.34B | $4.28B | $3.60B | $3.98B |
| Gross Profit | $6.95B | $6.96B | $6.58B | $5.95B | $5.91B |
| Gross Profit Ratio | 61.85% | 61.59% | 60.57% | 62.30% | 59.75% |
| Research and Development Expenses | $298.00M | $311.00M | $300.00M | $257.00M | $304.00M |
| General and Administrative Expenses | $4.45B | $2.27B | $4.48B | $4.09B | $4.22B |
| Selling and Marketing Expenses | $-119.00M | $2.02B | $2.03B | $1.94B | $- |
| Selling General and Administrative Expenses | $4.33B | $4.29B | $4.48B | $4.09B | $4.22B |
| Other Expenses | $111.00M | $366.00M | $-31.00M | $-31.00M | $-212.00M |
| Operating Expenses | $4.74B | $4.96B | $4.75B | $4.31B | $4.31B |
| Cost and Expenses | $9.03B | $9.31B | $9.03B | $7.91B | $8.29B |
| Interest Income | $92.00M | $14.00M | $51.00M | $17.00M | $14.00M |
| Interest Expense | $394.00M | $414.00M | $258.00M | $12.00M | $15.00M |
| Depreciation and Amortization | $196.00M | $309.00M | $287.00M | $268.00M | $305.00M |
| EBITDA | $2.51B | $2.35B | $2.18B | $2.21B | $1.91B |
| EBITDA Ratio | 22.38% | 20.80% | 19.92% | 20.44% | 19.26% |
| Operating Income | $2.21B | $2.00B | $1.82B | $1.64B | $1.60B |
| Operating Income Ratio | 19.64% | 17.66% | 16.81% | 17.16% | 16.15% |
| Total Other Income Expenses Net | $-296.00M | $-368.00M | $-207.00M | $-2.00M | $-7.00M |
| Income Before Tax | $1.91B | $1.63B | $1.62B | $1.64B | $1.59B |
| Income Before Tax Ratio | 17.00% | 14.40% | 14.90% | 17.14% | 16.08% |
| Income Tax Expense | $435.00M | $517.00M | $499.00M | $197.00M | $410.00M |
| Net Income | $1.44B | $1.05B | $1.06B | $1.39B | $1.15B |
| Net Income Ratio | 12.84% | 9.28% | 9.76% | 14.56% | 11.58% |
| EPS | $0.16 | $0.11 | $0.11 | $0.15 | $0.12 |
| EPS Diluted | $0.16 | $0.11 | $0.11 | $0.15 | $0.12 |
| Weighted Average Shares Outstanding | 9.18B | 9.26B | 9.23B | 9.23B | 9.23B |
| Weighted Average Shares Outstanding Diluted | 9.18B | 9.26B | 9.24B | 9.23B | 9.23B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.76B | $2.78B | $2.77B | $2.92B | $2.77B | $2.80B | $2.75B | $2.99B | $3.79B | $2.89B | $2.56B | $2.63B | $1.47B | $2.49B | $2.27B | $2.31B |
| Cost of Revenue | $1.11B | $1.03B | $979.00M | $1.08B | $1.28B | $1.08B | $1.04B | $1.15B | $1.59B | $1.07B | $963.00M | $1.01B | $545.00M | $933.00M | $846.00M | $904.00M |
| Gross Profit | $1.65B | $1.75B | $1.80B | $1.84B | $1.48B | $1.72B | $1.71B | $1.84B | $2.21B | $1.82B | $1.60B | $1.61B | $920.00M | $1.56B | $1.42B | $1.40B |
| Gross Profit Ratio | 59.88% | 62.88% | 64.70% | 63.00% | 53.50% | 61.30% | 62.10% | 61.60% | 58.20% | 62.90% | 62.40% | 61.40% | 62.80% | 62.50% | 62.70% | 60.80% |
| Research and Development Expenses | $78.00M | $76.00M | $73.00M | $71.00M | $94.00M | $75.00M | $67.00M | $75.00M | $117.00M | $82.00M | $72.00M | $64.00M | $39.00M | $74.00M | $55.00M | $54.00M |
| General and Administrative Expenses | $1.11B | $1.09B | $1.15B | $1.10B | $1.09B | $1.06B | $1.13B | $1.14B | $1.51B | $1.20B | $1.09B | $1.09B | $711.00M | $997.00M | $- | $- |
| Selling and Marketing Expenses | $-119.00M | $- | $-61.00M | $- | $2.02B | $- | $- | $- | $2.03B | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $987.00M | $1.09B | $1.09B | $1.10B | $1.09B | $1.06B | $1.13B | $1.14B | $1.51B | $1.20B | $1.09B | $1.09B | $711.00M | $997.00M | $981.00M | $1.01B |
| Other Expenses | $237.00M | $-124.00M | $138.00M | $- | $- | $- | $- | $3.00M | $- | $-28.00M | $-1.00M | $-3.00M | $1.00M | $-21.00M | $- | $- |
| Operating Expenses | $1.30B | $1.04B | $1.30B | $1.18B | $1.21B | $1.13B | $1.20B | $1.21B | $1.62B | $1.25B | $1.16B | $1.15B | $751.00M | $1.05B | $1.03B | $1.06B |
| Cost and Expenses | $2.41B | $2.08B | $2.28B | $2.26B | $2.50B | $2.21B | $2.24B | $2.36B | $3.21B | $2.32B | $2.13B | $2.16B | $1.30B | $1.98B | $1.88B | $1.97B |
| Interest Income | $49.00M | $12.00M | $9.00M | $22.00M | $2.00M | $88.00M | $28.00M | $10.00M | $38.00M | $7.00M | $36.00M | $7.00M | $- | $4.00M | $3.00M | $2.00M |
| Interest Expense | $111.00M | $90.00M | $96.00M | $97.00M | $133.00M | $88.00M | $124.00M | $95.00M | $244.00M | $81.00M | $71.00M | $8.00M | $- | $4.00M | $- | $- |
| Depreciation and Amortization | $49.00M | $11.00M | $6.00M | $47.75M | $47.75M | $46.25M | $76.00M | $46.25M | $46.25M | $44.75M | $66.00M | $44.75M | $44.75M | $54.25M | $60.00M | $54.25M |
| EBITDA | $511.00M | $716.00M | $502.00M | $687.00M | $317.00M | $584.00M | $542.00M | $637.00M | $635.00M | $576.00M | $470.00M | $473.00M | $129.00M | $511.00M | $453.00M | $475.25M |
| EBITDA Ratio | 18.52% | 25.76% | 18.09% | 23.19% | 11.03% | 20.87% | 19.69% | 21.33% | 16.32% | 19.92% | 18.35% | 18.01% | 8.81% | 20.52% | 19.96% | 20.61% |
| Operating Income | $350.00M | $705.00M | $496.00M | $662.00M | $271.00M | $584.00M | $514.00M | $627.00M | $581.00M | $569.00M | $434.00M | $466.00M | $169.00M | $507.00M | $393.00M | $339.00M |
| Operating Income Ratio | 12.69% | 25.36% | 17.87% | 22.68% | 9.80% | 20.87% | 18.68% | 21.00% | 15.32% | 19.67% | 16.95% | 17.74% | 11.54% | 20.36% | 17.32% | 14.70% |
| Total Other Income Expenses Net | $-62.00M | $-79.00M | $-90.00M | $-65.00M | $-99.00M | $-88.00M | $-96.00M | $-85.00M | $-206.00M | $-74.00M | $-35.00M | $-1.00M | $108.00M | $- | $-3.00M | $2.00M |
| Income Before Tax | $288.00M | $626.00M | $406.00M | $590.00M | $172.00M | $496.00M | $418.00M | $542.00M | $375.00M | $495.00M | $399.00M | $465.00M | $277.00M | $507.00M | $386.00M | $350.00M |
| Income Before Tax Ratio | 10.44% | 22.52% | 14.63% | 20.21% | 6.22% | 17.73% | 15.19% | 18.15% | 9.89% | 17.12% | 15.58% | 17.70% | 18.91% | 20.36% | 17.01% | 15.18% |
| Income Tax Expense | $66.00M | $127.00M | $93.00M | $149.00M | $165.00M | $122.00M | $103.00M | $127.00M | $158.00M | $130.00M | $212.00M | $108.00M | $-253.00M | $125.00M | $115.00M | $101.00M |
| Net Income | $231.00M | $485.00M | $303.00M | $423.00M | $-3.00M | $365.00M | $298.00M | $389.00M | $198.00M | $345.00M | $201.00M | $343.00M | $528.00M | $371.00M | $258.00M | $233.00M |
| Net Income Ratio | 8.37% | 17.45% | 10.92% | 14.49% | -0.11% | 13.05% | 10.83% | 13.03% | 5.22% | 11.93% | 7.85% | 13.06% | 36.04% | 14.90% | 11.37% | 10.10% |
| EPS | $0.03 | $0.05 | $0.03 | $4.60 | $0.00 | $0.08 | $0.06 | $0.09 | $0.02 | $0.07 | $0.04 | $0.07 | $0.11 | $0.08 | $0.03 | $0.03 |
| EPS Diluted | $0.03 | $0.05 | $0.03 | $4.60 | $0.00 | $0.08 | $0.06 | $0.09 | $0.02 | $0.07 | $0.04 | $0.07 | $0.11 | $0.08 | $0.03 | $0.03 |
| Weighted Average Shares Outstanding | 9.22B | 9.17B | 9.18B | 9.20B | 9.25B | 9.23B | 9.21B | 9.26B | 9.23B | 9.23B | 9.23B | 9.23B | 9.23B | 9.23B | 9.29B | 9.23B |
| Weighted Average Shares Outstanding Diluted | 9.22B | 9.17B | 9.21B | 9.20B | 9.25B | 9.23B | 9.27B | 9.26B | 9.26B | 9.23B | 9.23B | 9.23B | 9.23B | 9.23B | 9.23B | 9.23B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.25B | $1.04B | $684.00M | $414.00M | $334.00M |
| Short Term Investments | $- | $- | $- | $1.00M | $1.00M |
| Cash and Short Term Investments | $2.25B | $1.04B | $684.00M | $414.00M | $334.00M |
| Net Receivables | $2.06B | $1.35B | $1.49B | $3.83B | $3.59B |
| Inventory | $1.19B | $1.41B | $1.35B | $951.00M | $949.00M |
| Other Current Assets | $223.00M | $1.01B | $540.00M | $2.57B | $2.38B |
| Total Current Assets | $5.72B | $4.82B | $4.06B | $5.25B | $5.01B |
| Property Plant Equipment Net | $1.92B | $1.90B | $1.90B | $1.66B | $1.60B |
| Goodwill | $- | $8.32B | $8.40B | $8.25B | $8.27B |
| Intangible Assets | $26.21B | $18.54B | $20.04B | $18.95B | $18.95B |
| Goodwill and Intangible Assets | $26.21B | $26.86B | $28.44B | $27.20B | $27.22B |
| Long Term Investments | $82.00M | $65.00M | $44.00M | $23.00M | $41.00M |
| Tax Assets | $- | $- | $220.00M | $312.00M | $251.00M |
| Other Non-Current Assets | $383.00M | $415.00M | $157.00M | $8.00M | $10.00M |
| Total Non-Current Assets | $28.60B | $29.24B | $30.76B | $29.20B | $29.12B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $34.31B | $34.05B | $34.81B | $34.45B | $34.13B |
| Account Payables | $1.97B | $1.85B | $1.83B | $1.58B | $1.83B |
| Short Term Debt | $1.58B | $656.00M | $437.00M | $922.00M | $382.00M |
| Tax Payables | $286.00M | $288.00M | $210.00M | $237.00M | $278.00M |
| Deferred Revenue | $- | $- | $23.00M | $11.00M | $11.00M |
| Other Current Liabilities | $1.98B | $1.84B | $1.89B | $1.50B | $1.53B |
| Total Current Liabilities | $5.81B | $4.64B | $4.37B | $4.24B | $4.01B |
| Long Term Debt | $8.71B | $8.80B | $10.18B | $88.00M | $105.00M |
| Deferred Revenue Non-Current | $- | $- | $- | $281.00M | $401.00M |
| Deferred Tax Liabilities Non-Current | $- | $- | $3.60B | $3.36B | $3.37B |
| Other Non-Current Liabilities | $3.57B | $3.89B | $3.81B | $3.36B | $3.39B |
| Total Non-Current Liabilities | $12.28B | $12.69B | $13.99B | $3.73B | $3.89B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $18.09B | $17.33B | $18.36B | $7.97B | $7.91B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $91.00M | $92.00M | $92.00M | $1.00M | $1.00M |
| Retained Earnings | $27.27B | $27.47B | $26.73B | $37.99B | $37.76B |
| Accumulated Other Comprehensive Income Loss | $- | $- | $1.20B | $-11.63B | $-11.65B |
| Other Total Stockholders Equity | $-11.20B | $-10.96B | $-11.69B | $-448.00M | $- |
| Total Stockholders Equity | $16.17B | $16.61B | $16.33B | $26.36B | $26.11B |
| Total Equity | $16.22B | $16.73B | $16.46B | $26.48B | $26.22B |
| Total Liabilities and Stockholders Equity | $34.31B | $34.05B | $34.81B | $34.45B | $34.13B |
| Minority Interest | $58.00M | $123.00M | $126.00M | $125.00M | $111.00M |
| Total Liabilities and Total Equity | $34.31B | $34.05B | $34.81B | $34.45B | $34.13B |
| Total Investments | $82.00M | $65.00M | $44.00M | $1.00M | $1.00M |
| Total Debt | $10.29B | $9.46B | $10.44B | $991.00M | $487.00M |
| Net Debt | $8.04B | $8.41B | $9.76B | $577.00M | $153.00M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | April 03, 2023 | December 31, 2022 | November 14, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.25B | $- | $531.00M | $-1.04B | $1.04B | $-490.00M | $490.00M | $-684.00M | $606.00M | $-1.33B | $1.33B | $383.00M | $414.00M | $-334.00M |
| Short Term Investments | $- | $- | $-6.00M | $2.09B | $- | $980.00M | $- | $1.37B | $78.00M | $2.67B | $- | $- | $1.00M | $668.00M |
| Cash and Short Term Investments | $2.25B | $531.00M | $531.00M | $1.04B | $1.04B | $490.00M | $490.00M | $684.00M | $684.00M | $1.33B | $1.33B | $383.00M | $414.00M | $334.00M |
| Net Receivables | $2.06B | $- | $2.14B | $- | $1.35B | $- | $2.04B | $- | $1.49B | $- | $2.41B | $2.42B | $1.32B | $- |
| Inventory | $1.19B | $- | $1.46B | $- | $1.41B | $- | $1.50B | $- | $1.35B | $- | $1.15B | $986.00M | $951.00M | $- |
| Other Current Assets | $223.00M | $- | $581.00M | $- | $1.01B | $- | $166.00M | $- | $540.00M | $- | $9.51B | $11.51B | $2.57B | $- |
| Total Current Assets | $5.72B | $531.00M | $4.71B | $1.04B | $4.82B | $490.00M | $4.20B | $684.00M | $4.06B | $1.33B | $14.40B | $15.30B | $5.25B | $334.00M |
| Property Plant Equipment Net | $1.92B | $- | $1.86B | $- | $1.90B | $- | $1.85B | $- | $1.90B | $- | $1.77B | $1.69B | $1.66B | $- |
| Goodwill | $- | $- | $- | $- | $8.32B | $- | $- | $- | $8.40B | $- | $- | $- | $8.25B | $- |
| Intangible Assets | $26.21B | $- | $26.37B | $- | $18.54B | $- | $27.67B | $- | $20.04B | $- | $28.54B | $27.69B | $18.95B | $- |
| Goodwill and Intangible Assets | $26.21B | $- | $26.37B | $- | $26.86B | $- | $27.67B | $- | $28.44B | $- | $28.54B | $27.69B | $27.20B | $- |
| Long Term Investments | $82.00M | $- | $87.00M | $- | $101.00M | $- | $87.00M | $- | $44.00M | $321.00M | $- | $8.00M | $23.00M | $- |
| Tax Assets | $- | $- | $- | $- | $265.00M | $- | $241.00M | $- | $220.00M | $- | $203.00M | $314.00M | $312.00M | $- |
| Other Non-Current Assets | $383.00M | $-531.00M | $371.00M | $-1.04B | $114.00M | $-490.00M | $113.00M | $-684.00M | $157.00M | $-1.66B | $88.00M | $24.00M | $8.00M | $-334.00M |
| Total Non-Current Assets | $28.60B | $-531.00M | $28.69B | $-1.04B | $29.24B | $-490.00M | $29.96B | $-684.00M | $30.76B | $-1.33B | $30.61B | $29.73B | $29.20B | $-334.00M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $11.51B | $- | $- | $- | $- |
| Total Assets | $34.31B | $- | $33.40B | $- | $34.05B | $- | $34.16B | $- | $34.81B | $11.51B | $45.01B | $45.02B | $34.45B | $- |
| Account Payables | $1.97B | $- | $3.60B | $- | $1.85B | $- | $3.51B | $- | $1.83B | $- | $3.55B | $3.14B | $1.58B | $- |
| Short Term Debt | $1.58B | $- | $1.45B | $- | $656.00M | $- | $1.13B | $- | $437.00M | $684.00M | $335.00M | $110.00M | $922.00M | $- |
| Tax Payables | $286.00M | $- | $308.00M | $- | $288.00M | $- | $297.00M | $- | $210.00M | $- | $236.00M | $242.00M | $237.00M | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $242.00M | $- | $- |
| Other Current Liabilities | $1.98B | $- | $266.00M | $- | $1.84B | $- | $54.00M | $- | $1.89B | $-684.00M | $82.00M | $1.53B | $1.50B | $- |
| Total Current Liabilities | $5.81B | $- | $5.62B | $- | $4.64B | $- | $4.99B | $- | $4.37B | $684.00M | $4.20B | $5.03B | $4.24B | $- |
| Long Term Debt | $8.71B | $- | $7.41B | $- | $8.95B | $- | $8.95B | $- | $10.18B | $11.35B | $9.97B | $9.38B | $88.00M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $346.00M | $- | $381.00M | $- | $- | $- | $- | $- | $281.00M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $3.49B | $- | $3.44B | $- | $3.60B | $- | $3.65B | $3.47B | $3.36B | $- |
| Other Non-Current Liabilities | $3.57B | $-16.71B | $3.66B | $- | $3.39B | $- | $3.28B | $- | $3.81B | $160.00M | $3.83B | $3.76B | $3.36B | $- |
| Total Non-Current Liabilities | $12.28B | $-16.71B | $11.06B | $- | $12.69B | $- | $12.61B | $- | $13.99B | $11.51B | $13.81B | $13.15B | $3.73B | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-684.00M | $- | $- | $- | $- |
| Total Liabilities | $18.09B | $-16.71B | $16.69B | $- | $17.33B | $- | $17.60B | $- | $18.36B | $11.51B | $18.01B | $18.17B | $7.97B | $- |
| Preferred Stock | $- | $- | $11.02B | $- | $10.96B | $- | $10.88B | $- | $- | $- | $300.00K | $- | $11.18B | $- |
| Common Stock | $91.00M | $- | $91.00M | $- | $92.00M | $- | $92.00M | $- | $92.00M | $- | $1.00M | $1.00M | $1.00M | $- |
| Retained Earnings | $27.27B | $- | $27.53B | $- | $27.47B | $- | $27.24B | $- | $26.73B | $- | $38.38B | $38.21B | $37.99B | $- |
| Accumulated Other Comprehensive Income Loss | $- | $16.60B | $- | $16.61B | $-10.96B | $16.45B | $-10.88B | $16.33B | $1.20B | $26.89B | $-11.55B | $-11.50B | $-11.18B | $26.11B |
| Other Total Stockholders Equity | $-11.20B | $107.00M | $-22.03B | $123.00M | $-21.92B | $117.00M | $-21.77B | $126.00M | $-11.69B | $104.00M | $-11.48B | $- | $-22.37B | $111.00M |
| Total Stockholders Equity | $16.17B | $16.71B | $16.60B | $16.73B | $16.61B | $16.57B | $16.45B | $16.46B | $16.33B | $27.00B | $26.89B | $26.71B | $26.36B | $26.22B |
| Total Equity | $16.22B | $16.71B | $16.71B | $16.73B | $16.73B | $16.57B | $16.57B | $16.46B | $16.46B | $27.00B | $27.00B | $26.85B | $26.48B | $26.22B |
| Total Liabilities and Stockholders Equity | $34.31B | $- | $33.40B | $16.73B | $34.05B | $16.57B | $34.16B | $16.46B | $34.81B | $27.00B | $45.01B | $45.02B | $34.45B | $26.22B |
| Minority Interest | $58.00M | $- | $107.00M | $- | $123.00M | $- | $117.00M | $- | $126.00M | $- | $104.00M | $139.00M | $125.00M | $- |
| Total Liabilities and Total Equity | $34.31B | $- | $33.40B | $16.73B | $34.05B | $16.57B | $34.16B | $16.46B | $34.81B | $27.00B | $45.01B | $45.02B | $34.45B | $26.22B |
| Total Investments | $82.00M | $- | $81.00M | $2.09B | $101.00M | $980.00M | $87.00M | $1.37B | $78.00M | $2.67B | $- | $8.00M | $1.00M | $668.00M |
| Total Debt | $10.29B | $- | $8.86B | $- | $9.46B | $- | $9.87B | $- | $10.44B | $12.04B | $10.25B | $9.44B | $991.00M | $- |
| Net Debt | $8.04B | $- | $8.33B | $1.04B | $8.41B | $490.00M | $9.38B | $684.00M | $9.83B | $13.37B | $8.92B | $9.06B | $577.00M | $334.00M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $1.44B | $1.11B | $1.12B | $1.44B | $1.18B |
| Depreciation and Amortization | $324.00M | $309.00M | $287.00M | $268.00M | $305.00M |
| Deferred Income Tax | $- | $- | $62.00M | $197.00M | $410.00M |
| Stock Based Compensation | $102.00M | $76.00M | $15.00M | $59.00M | $63.00M |
| Change in Working Capital | $48.00M | $-107.00M | $181.00M | $-152.00M | $15.00M |
| Accounts Receivables | $-312.00M | $38.00M | $-85.00M | $14.00M | $18.00M |
| Inventory | $216.00M | $-131.00M | $-292.00M | $-17.00M | $130.00M |
| Accounts Payables | $- | $112.00M | $387.00M | $41.00M | $140.00M |
| Other Working Capital | $144.00M | $-126.00M | $171.00M | $-190.00M | $-273.00M |
| Other Non Cash Items | $385.00M | $711.00M | $353.00M | $-20.00M | $198.00M |
| Net Cash Provided by Operating Activities | $2.30B | $2.10B | $2.06B | $1.36B | $1.41B |
| Investments in Property Plant and Equipment | $-250.00M | $-234.00M | $-328.00M | $-298.00M | $-318.00M |
| Acquisitions Net | $- | $-71.00M | $9.21B | $112.00M | $241.00M |
| Purchases of Investments | $- | $- | $-9.21B | $-112.00M | $96.00M |
| Sales Maturities of Investments | $- | $- | $700.00M | $100.00M | $158.00M |
| Other Investing Activities | $778.00M | $171.00M | $-9.16B | $165.00M | $853.00M |
| Net Cash Used for Investing Activities | $528.00M | $-134.00M | $-8.78B | $-33.00M | $1.03B |
| Debt Repayment | $592.00M | $-553.00M | $9.49B | $8.00M | $28.00M |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-121.00M | $-38.00M | $- | $- | $- |
| Dividends Paid | $-570.00M | $-388.00M | $-2.68B | $-1.15B | $-2.37B |
| Other Financing Activities | $-1.44B | $-627.00M | $107.00M | $-96.00M | $-94.00M |
| Net Cash Used Provided by Financing Activities | $-1.54B | $-1.57B | $6.91B | $-1.24B | $-2.44B |
| Effect of Forex Changes on Cash | $-79.00M | $-15.00M | $15.00M | $-5.00M | $-6.00M |
| Net Change in Cash | $1.21B | $383.00M | $205.00M | $82.00M | $-6.00M |
| Cash at End of Period | $2.21B | $994.00M | $611.00M | $405.00M | $323.00M |
| Cash at Beginning of Period | $994.00M | $611.00M | $406.00M | $323.00M | $329.00M |
| Operating Cash Flow | $2.30B | $2.10B | $2.06B | $1.36B | $1.41B |
| Capital Expenditure | $-250.00M | $-336.00M | $-328.00M | $-298.00M | $-318.00M |
| Free Cash Flow | $2.05B | $1.76B | $1.74B | $1.06B | $1.09B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $231.00M | $485.00M | $303.00M | $423.00M | $-3.00M | $365.00M | $298.00M | $389.00M | $198.00M | $345.00M | $174.00M | $343.00M | $528.00M | $371.00M | $258.00M | $233.00M |
| Depreciation and Amortization | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $102.00M | $- | $49.00M | $- | $88.00M | $- | $36.00M | $- | $78.00M | $- | $- | $- | $59.00M | $- | $- | $- |
| Change in Working Capital | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non Cash Items | $-333.00M | $-485.00M | $-352.00M | $-423.00M | $-85.00M | $-365.00M | $-334.00M | $-389.00M | $-276.00M | $-345.00M | $-174.00M | $-343.00M | $-587.00M | $-371.00M | $-258.00M | $-233.00M |
| Net Cash Provided by Operating Activities | $- | $- | $- | $- | $- | $- | $- | $- | $61.00M | $- | $- | $- | $- | $- | $- | $- |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $- | $- | $- | $- | $- | $- | $- | $- | $61.00M | $- | $- | $- | $- | $- | $- | $- |
| Cash at End of Period | $- | $- | $- | $- | $- | $- | $- | $684.00M | $684.00M | $- | $- | $- | $- | $- | $- | $- |
| Cash at Beginning of Period | $- | $- | $- | $- | $- | $- | $- | $684.00M | $623.00M | $- | $- | $- | $- | $- | $- | $- |
| Operating Cash Flow | $- | $- | $- | $- | $- | $- | $- | $- | $61.00M | $- | $- | $- | $- | $- | $- | $- |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $- | $- | $- | $- | $- | $- | $- | $- | $61.00M | $- | $- | $- | $- | $- | $- | $- |
Haleon plc Dividends
Explore Haleon plc's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
1.29%
Dividend Payout Ratio
36.99%
Dividend Paid & Capex Coverage Ratio
2.90x
Haleon plc Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.11661 | $0.11661 | April 25, 2025 | April 25, 2025 | June 05, 2025 | February 27, 2025 |
| $0.051416 | $0.051416 | August 16, 2024 | August 16, 2024 | September 19, 2024 | August 01, 2024 |
| $0.10635 | $0.10635 | March 14, 2024 | March 15, 2024 | May 16, 2024 | February 29, 2024 |
| $0.0459936 | $0.0459936 | August 24, 2023 | August 25, 2023 | October 05, 2023 | August 02, 2023 |
| $0.0577 | $0.0577 | March 16, 2023 | March 17, 2023 | April 27, 2023 | March 02, 2023 |
Haleon plc News
Read the latest news about Haleon plc, including recent articles, headlines, and updates.
Haleon buys £170m of shares as Pfizer offloads final stake
Haleon PLC (LSE:HLN, NYSE:HLN) has bought roughly £170 million of its shares back from former parent company Pfizer Inc (NYSE:PFE, ETR:PFE). The FTSE 100-listed maker of toothpaste and vitamins paid 385p per share for the off-market purchase, which is part of a previous agreement when Haleon was spun out in 2022 that its former parent companies, GSK being the other, would eventually cut their stakes.
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve next year.
Haleon: Growing Profits And Dividend
I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices.
Haleon figures meet expectations; but analysts and investors wanted more
Haleon PLC's (LSE:HLN, NYSE:HLN) prelims have reassured investors, with earnings per share (EPS) beating expectations by 6% in the second half of 2024, according to analysts - although the shares succumbed to a bout of profit taking in their wake. The consumer health giant reported 5% organic growth for the year, slightly ahead of market forecasts, Stifel said.
Haleon plc (HLN) Q4 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q4 2024 Earnings Conference Call February 27, 2025 4:00 AM ET Company Participants Jo Russell - Head-Investor Relations Brian McNamara - Chief Executive Officer Dawn Allen - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS David Hayes - Jefferies Rashad Kawan - Morgan Stanley Chris Pitcher - Redburn Tom Sykes - Deutsche Bank Jo Russell Good morning, everyone. Welcome to Haleon's Full Year 2024 Q&A call.
Haleon: Investors unimpressed by growth target and £500m buyback as shares slide 3.2%
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.2% in early trading as investors saw little in the results to justify further gains at current valuations. While full-year sales and profits met expectations, analysts noted a lack of clear catalysts.
Haleon results could provide tonic for investor anxiety, says Barclays
When Haleon PLC (LSE:HLN, NYSE:HLN) reports results on Thursday, 27 February, Barclays expects its sales of painkillers to have offset the "well known headwind" from a weak start to the cold and flu season in the final quarter of 2024. Analysts at the bank said that earnings delivery and profit margin expansion are the main areas of focus for investors in the FTSE 100 consumer health products group too, while Futura Medical investors are likely to be keeping an eye out for news on the Eroxon collaboration.
Pfizer to further reduce stake in Haleon through share sale
Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building process targeting institutional investors. Currently holding 15% of the Panadol maker, Pfizer expects to reduce its interest to about 7.3 per cent upon completion.
TUMS Teams Up with DraftKings to Launch TUMS Fantasy Foodball Pool, Making Gameday Food Dreams a Reality
Fans can draft their top food and drink picks for a free shot at winning a share of $40,000 in total cash prizes WARREN, N.J. , Jan. 9, 2025 /PRNewswire/ -- As hundreds of millions prepare to tune into the biggest day in football, a new survey from TUMS has revealed that 1 in 4 viewers will be focused on the real MVP: the food.
Haleon: Guidance Implies Uncertainty Around Flu Season
Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3.
Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation
WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024.
Haleon plc (HLN) Q3 2024 Sales Call Transcript
Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO.
Panadol maker Haleon takes hit from currency headwinds
Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%.
Haleon gets target hike as UBS raises 'forever' sales target
Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth.
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.
Haleon's buy rating restated after Pfizer cuts down stake
UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.
Haleon buys back some shares as Pfizer sells down stake
Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker. The FTSE 100 consumer health group said made the purchase at a price of 308p per share.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for HLN.